Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders
Open Access
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 17, 100335
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
- King's College London
- South London and Maudsley NHS Foundation Trust
This publication has 68 references indexed in Scilit:
- Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled studyJournal of Affective Disorders, 2012
- Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label studyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- Towards a glutamate hypothesis of depressionNeuropharmacology, 2012
- A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiation Factor eIF4AIPLOS ONE, 2010
- Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood DisordersBiological Psychiatry, 2010
- A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase SchizophreniaThe Journal of Clinical Psychiatry, 2009
- Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in miceMolecular Psychiatry, 2008
- Stress, Depression, and Neuroplasticity: A Convergence of MechanismsNeuropsychopharmacology, 2007
- Microglia-mediated neurotoxicity: uncovering the molecular mechanismsNature Reviews Neuroscience, 2007
- Minocycline exerts inhibitory effects on multiple mitogen‐activated protein kinases and IκBα degradation in a stimulus‐specific manner in microgliaJournal of Neurochemistry, 2005